Text Size

Arizona Cancer Center Biospecimen Repository

This study is currently recruiting participants.
Verified October 2010 by University of Arizona
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
University of Arizona
ClinicalTrials.gov Identifier:
NCT00896935
First received: May 9, 2009
Last updated: October 20, 2010
Last verified: October 2010
History of Changes
  Purpose

RATIONALE: Collecting and storing samples of tissue and blood from patients with cancer to test in the laboratory may help the study of cancer in the future.

PURPOSE: This research study is collecting and storing tumor, tissue, and blood samples from patients with pancreatic cancer.


Condition Intervention
Cancer
 Other: biologic sample preservation procedure

Study Type: Observational
Official Title: Arizona Cancer Center Biospecimen Repository

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by University of Arizona:

Primary Outcome Measures:
  • Provision of tissue samples and biospecimens for translational study [ Time Frame: An eletronic record of the specimens is kept in a secure, web-based database. Follow-up information from patients will be obtained from the patient medical record, and updated every 6 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Tissue will be collected and preserved from the primary organ site, from the metastases, from patient blood (serum and lymphocytes), from patient urine, and from related samples of other tissues/fluids removed by the surgeon left over after diagnostic testing.


Estimated Enrollment: 1000
Study Start Date: July 2006
Estimated Primary Completion Date: July 2020 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: biologic sample preservation procedure
    biologic sample preservation procedure
    Other Name: biologic sample preservation procedure
Detailed Description:

OBJECTIVES:

  • Provide cancer investigators access to a wide variety of tissues and biospecimens for translational studies in cancer.
  • Collect and preserve tissue from the primary organ site (uninvolved and involved with cancer), from the metastases, from patient blood (serum and lymphocytes), and from patient urine.
  • Provide quality-controlled storage and management of the specimen bank.
  • Collect relevant clinical and pathologic information with appropriate privacy protection.
  • Contribute to the development of a comprehensive database annotated with relevant clinical data, pathology, and research findings.

OUTLINE: This is a multicenter study.

Tumor samples, lymph node samples, and normal pancreas tissue samples are collected. Blood samples are also collected prior to surgery, six months after the initial blood draw and tissue sample collection, and every six months thereafter for two years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The goal of this protocol is to provide cancer investigators access to a wide variety of tissues and biospecimens for translational studies in cancer by collecting and preserving tissue from the primary organ site, from the metastases, from patient blood (serum and lymphocytes), from patient urine, and from related samples of other tissues/fluids removed by the surgeon left over after diagnostic testing. No additional tissue will be taken at the time of surgery other than that required for patient care, but additional blood and urine samples will be obtained at that time. This protocol is not limited to certain types of cancer.

Criteria

DISEASE CHARACTERISTICS:

  • Patient who is seen at the Arizona Cancer Center or University Medical Center and will undergo any surgery or procedure for cancer

PATIENT CHARACTERISTICS:

  • NA

PRIOR CONCURRENT THERAPY:

  • NA

As this is a biospecimen repository, participation is open to all cancer patients being treated at the Arizona Cancer Center or University Medical Center by investigators on this protocol.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00896935

Locations
United States, Arizona
Arizona Cancer Center at University of Arizona Health Sciences Center Recruiting
Tucson, Arizona, United States, 85724-5024
Contact: Setsuko K. Chambers, MD     866-278-1554        
Sponsors and Collaborators
University of Arizona
National Cancer Institute (NCI)
Investigators
Principal Investigator: Setsuko K. Chambers, MD University of Arizona
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Setsuko K. Chambers, Arizona Cancer Center at University of Arizona Health Sciences Center
ClinicalTrials.gov Identifier: NCT00896935     History of Changes
Other Study ID Numbers: CDR0000597579, P30CA023074, UARIZ-06-0609-04, UARIZ-BIO#A06035, UARIZ-SRC18042
Study First Received: May 9, 2009
Last Updated: October 20, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Arizona:
cancer

ClinicalTrials.gov processed this record on May 16, 2013